Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 14;13:973085. doi: 10.3389/fimmu.2022.973085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yin, Ling, Wei, He, Wang, Hu, Lin, Nie, Chen, Lin, Zhou, Xie, Yun, Xie, Xue and Cai

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Intratumoral TLSs are associated with therapeutic response, survival risk, prognostic accuracy, and probability of overall survival in EBVaGC patients. (A) Kaplan-Meier curves showed different responses to adjuvant chemotherapy in different subgroups of patients in the SYSUCC cohort (log-rank test). (B) Kaplan-Meier curves showed that the three risk factors successfully stratified risk for the predicted survival of patients with EBVaGC in the SYSUCC cohort (log-rank test). (C) ROC curves compare the prognostic accuracy of the combined risk factors and any single independent risk factor in EBVaGC patients. Risk1: presence of at most one risk factors; Risk2: presence of two risk factors; Risk3: presence of three risk factors. (D) Nomogram for predicting the overall survival of EBVaGC patients with the independent factors. (E, F) The calibration curve for predicting patient overall survival at 2 years and 4 years in the SYSUCC cohort. (G) The calibration curve for predicting patient overall survival at 4 years of the validation cohort. EBVaGC, Epstein-Barr virus associated gastric cancer; ROC, receiver operator characteristic.